Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CARDINAL kidney study holding steady
June 2018
SHARING OPTIONS:

IRVING, Texas—In a recent update on the company’s Phase 2 CARDINAL study, investigating bardoxolone methyl in patients with chronic kidney disease due to Alport syndrome, Reata Pharmaceuticals Inc. has reported that efficacy results show significant increases in kidney function as measured by estimated glomerular filtration rate (eGFR). These increases were maintained through week 36 of the study, which is slated to run two years. Mean improvement from baseline eGFR at week 36 was 11.3 mL/min/1.73 m2, not significantly different from the change seen at week 12. The increases in urinary albumin to creatinine ratio, attributed to increased eGFR, have stabilized, and adverse events have been largely mild to moderate. No drug-related serious adverse events have been reported thus far.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.